|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Def.*** | ***During Elite Control*** |  |  |  | ***During ART-naïve follow-up*** |  |  | ***Time (months) from SC to first HIV-RNA*** | ***# HIV-RNA measurements within 6 months of HIV positive*** |
|  | ***# HIV-RNA measured*** | ***# CD4 measured*** | ***CD4 slope***† ***p-value*** |  | ***# HIV-RNA measured*** | ***# CD4 measured*** | ***CD4 slope***† ***p-value*** |
| **Aғ** | 11 | 11 | 0·03 |  | 13 | 11 | < 0·001 | 8 (1, 27) | 2 |
| **Bғ** | 10 | 10 | < 0·001 |  | 12 | 10 | < 0·001 | 6 (1, 25) | 2 |
| **Cғ** | 8 | 9 | < 0·001 |  | 11 | 9 | < 0·001 | 9 (2, 24) | 1 |
| **Dғ** | 9 | 10 | < 0·001 |  | 11 | 10 | < 0·001 | 8 (3, 18) | 2 |
| **Eғ** | 12 | 12 | 0·01 |  | 15 | 12 | 0·002 | 10 (2, 32) | 1 |
| **Fғ** | 9 | 10 | 0·05 |  | 14 | 10 | 0·001 | 17 (7, 42) | 1 |
| **Gғ** | 12 | 12 | < 0·001 |  | 14 | 12 | < 0·001 | 9 (2, 29) | 2 |
| **Hғ** | 17 | 19 | < 0·001 |  | 19 | 19 | < 0·001 | 17 (6, 53) | 1 |
| **Iғ** | 2 | 11 | 0·39 |  | 2 | 11 | 0·53 | 126 (93, 149) | 0 |
| **Jғ** | 15 | 21 | 0·19 |   | 19 | 21 | < 0·001 | 60 (30, 130) | 0 |